Faculty

Institution

Unit

Venue

Yesid Alvarado - Valero

Assistant Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Section Of Molecular Hematology And Therapy

Department Of Leukemia

Yesid Alvarado-Valero is an Assistant Professor at The University of Texas MD Anderson Cancer Center. His research focuses on hematological malignancies, particularly acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia, with an emphasis on optimizing frontline intensive chemotherapy, triplet regimens combining hypomethylating agents with venetoclax and isocitrate dehydrogenase inhibitors, and novel all-oral combination therapies. He has published extensively on targeted agents, including dasatinib, blinatumomab, and revumenib, with recent work appearing in Nature Communications, Blood, and the Journal of Clinical Oncology. His clinical trials research integrates pharmacology, pharmacotherapy, and immunology to advance treatment paradigms for leukemia and myeloid neoplasia.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Yesid Alvarado - Valero

The University of Texas MD Anderson Cancer Center

Assistant Professor

You can click a keyword to filter the displayed items

hematology medicine leukemia oncology hematological malignancies myeloid neoplasia pharmacology pharmacotherapy cancer research immunology clinical trials malignant blood disorders acute myeloid leukemia medicinal research bone marrow transplantation lymphoid neoplasia oncogenes phase ii study therapeutic targets clinical research cancer treatment cancer immunotherapy cancer care immunotherapy urology clinical transplantation surgical oncology inotuzumab ozogamicin mixed-phenotype acute leukemia disease progression laboratory medicine applied pharmacology vascular biology therapeutic efficacy novel therapies phase ii trial thrombosis blood transfusion chronic myeloid leukemia myelodysplastic syndromes myelodysplastic syndrome cellular therapy cancer discovery cancer cells anti-cancer agents hemostasis phase 2 older patients cohort studies histopathology clinical therapeutics anticoagulants frontline therapy cancer genetics prospective cohort studies aplastic anemia drug trials intensive chemotherapy laboratory hematology treatment options cytogenetics immune checkpoint inhibitors adult t-cell leukemia-lymphoma high-risk myelodysplastic syndrome malignant disease first-line treatment retrospective cohort studies cancer biology relapse prevention multi-scale studies acute myeloid leukaemia sequential blinatumomab later adulthood therapy resistance older adults disease assessment

Notable Scholarly Works

Notable Federal Grants

Collaborators

Evaluating the Impact of Fewer Frontline Intensive Chemotherapy Plus Venetoclax Consolidation Cycles on Outcomes in Aml. American Journal of Hematology (2026)

medicineoutcomes researchmetronomic chemotherapycancer carecombined modality treatmentcancer managementradiation oncologycancer researchmetronomic therapypharmacotherapyclinical trialsoncologycancer treatmentcancer letter

Outcomes of Patients Treated With Dasatinib 50 Mg/D: A Pooled Analysis. Clinical Lymphoma Myeloma & Leukemia (2026)

hematological malignanciespooled analysismedicineleukemiahematologyradiation oncologycancer researchpharmacotherapyclinical trialsoncologydasatinib 50cancer treatment

Addition of Obinutuzumab After One Year of Combined Acalabrutinib and Venetoclax is Safer and Effective Than Early Obinutuzumab in a Randomized Phase II Trial for Treatment NaïVe Cll. Blood (2025)

immunologymedicinepharmacologysystemic treatmenttreatment naïve cllclinical therapeuticspharmacotherapytherapeutic targetsapplied pharmacologyclinical trialsoncologycancer treatmentcombined acalabrutinibexperimental medicine

Aml-150: A Phase 1B/2 Trial of an All-Oral “Triplet” Regimen for Idh-Mutated Myeloid Malignancies: Decitabine or Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib. Clinical Lymphoma Myeloma & Leukemia (2025)

hematological malignanciesmedicineleukemiamyeloid neoplasiahematologycancer researchpharmacotherapyphase 1b/2idh-mutated myeloid malignanciesoncologyoncogenespathology

A Phase 2 Study of Cpx‐351 in Combination With Venetoclax in Patients With Newly Diagnosed High‐Risk Acute Myeloid Leukemia. HemaSphere (2025)

hematological malignanciesmedicineleukemiamyeloid neoplasiahematologycancer researchpharmacotherapycancer discoveryphase 2mixed-phenotype acute leukemiaoncologyoncogenesmalignant blood disorderscancer letterpathology

A Phase I/II Trial of Azacitidine and Venetoclax in Previously Untreated Myelodysplastic Syndromes. Blood (2025)

hematological malignanciesphase i/ii trialmedicineleukemiapharmacologymyeloid neoplasiahematologypharmacotherapyclinical trialspathologymyelodysplastic syndromes

A Phase II Trial of Azacitidine With Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome. Haematologica (2025)

medicinepharmacologymyeloid neoplasiahematologypharmacotherapyclinical trialsphase ii trialmyelodysplastic syndrome

Asxl1 Mutations Are Associated With Adverse Outcomes in European Leukemianet (Eln) 2024 Favorable Risk Patients With Acute Myeloid Leukemia (Aml) Treated With Venetoclax (Ven) Containing Low-Intensity Therapy (Lit). Blood (2025)

hematological malignanciesmedicineleukemiamyeloid neoplasiahematologycancer researcheuropean leukemianetoncologyoncogenesacute myeloid leukemiaasxl1 mutationspathology

Barriers to Allogeneic Stem Cell Transplantation in Responding Patients With Tp53-Mutated Acute Myeloid Leukemia. Bone Marrow Transplantation (2025)

immunologymedicineleukemiastem cell researchcell therapyhematologystem cellsbone marrow transplantationcell transplantationcellular therapystem cell transplantation

Bemcentinib as Monotherapy and in Combination With Low-Dose Cytarabine in Acute Myeloid Leukemia Patients Unfit for Intensive Chemotherapy: A Phase 1B/2A Trial. Nature Communications (2025)

hematological malignanciesmedicineleukemiapharmacologymyeloid neoplasiahematologypharmacotherapytherapeutic targetsapplied pharmacologyintensive chemotherapyclinical trialsoncologymedicinal researchphase 1b/2alow-dose cytarabine

1
2
3
4
5
37
10 / page

Yesid Alvarado - Valero

Assistant Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Section Of Molecular Hematology And Therapy

Department Of Leukemia

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Yesid Alvarado - Valero

The University of Texas MD Anderson Cancer Center

Assistant Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Evaluating the Impact of Fewer Frontline Intensive Chemotherapy Plus Venetoclax Consolidation Cycles on Outcomes in Aml. American Journal of Hematology (2026)

Outcomes of Patients Treated With Dasatinib 50 Mg/D: A Pooled Analysis. Clinical Lymphoma Myeloma & Leukemia (2026)

hematological malignanciespooled analysismedicineleukemiahematologyradiation oncologycancer researchpharmacotherapyclinical trialsoncologydasatinib 50cancer treatment

Addition of Obinutuzumab After One Year of Combined Acalabrutinib and Venetoclax is Safer and Effective Than Early Obinutuzumab in a Randomized Phase II Trial for Treatment NaïVe Cll. Blood (2025)

hematological malignanciesmedicineleukemiamyeloid neoplasiahematologycancer researchpharmacotherapyphase 1b/2idh-mutated myeloid malignanciesoncologyoncogenespathology

A Phase 2 Study of Cpx‐351 in Combination With Venetoclax in Patients With Newly Diagnosed High‐Risk Acute Myeloid Leukemia. HemaSphere (2025)

A Phase I/II Trial of Azacitidine and Venetoclax in Previously Untreated Myelodysplastic Syndromes. Blood (2025)

hematological malignanciesphase i/ii trialmedicineleukemiapharmacologymyeloid neoplasiahematologypharmacotherapyclinical trialspathologymyelodysplastic syndromes

A Phase II Trial of Azacitidine With Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome. Haematologica (2025)

medicinepharmacologymyeloid neoplasiahematologypharmacotherapyclinical trialsphase ii trialmyelodysplastic syndrome

hematological malignanciesmedicineleukemiamyeloid neoplasiahematologycancer researcheuropean leukemianetoncologyoncogenesacute myeloid leukemiaasxl1 mutationspathology

Barriers to Allogeneic Stem Cell Transplantation in Responding Patients With Tp53-Mutated Acute Myeloid Leukemia. Bone Marrow Transplantation (2025)

immunologymedicineleukemiastem cell researchcell therapyhematologystem cellsbone marrow transplantationcell transplantationcellular therapystem cell transplantation

Bemcentinib as Monotherapy and in Combination With Low-Dose Cytarabine in Acute Myeloid Leukemia Patients Unfit for Intensive Chemotherapy: A Phase 1B/2A Trial. Nature Communications (2025)

1
2
3
4
5
37
10 / page